Dr James Buteau completed his nuclear medicine specialisation in Canada, where he practiced for 2 years. Since 2019, he has worked at Peter Mac as a clinical and research fellow in the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC). Dr Buteau is in the second year of his PhD, under the supervision of Prof Michael Hofman and A/Prof Arun Azad. He published the TheraP trial PET imaging biomarkers analysis in the Lancet Oncology as first author. He is currently investigating the role of PSMA PET/CT for prostate cancer diagnosis in the PRIMARY2 trial, and Terbium-161-PSMA therapy for men with mCRPC in the VIOLET trial.